ArticleCancer immunology, immunotherapy : CII2025
Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Yang Tan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.